1. Home
  2. SEVN vs ALXO Comparison

SEVN vs ALXO Comparison

Compare SEVN & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seven Hills Realty Trust

SEVN

Seven Hills Realty Trust

N/A

Current Price

$6.70

Market Cap

167.9M

Sector

Real Estate

ML Signal

N/A

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

N/A

Current Price

$1.12

Market Cap

172.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SEVN
ALXO
Founded
1986
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
167.9M
172.8M
IPO Year
2008
2020

Fundamental Metrics

Financial Performance
Metric
SEVN
ALXO
Price
$6.70
$1.12
Analyst Decision
Buy
Strong Buy
Analyst Count
5
7
Target Price
★ $8.70
$4.60
AVG Volume (30 Days)
175.7K
★ 1.4M
Earning Date
10-27-2026
11-24-2026
Dividend Yield
★ 16.72%
N/A
EPS Growth
N/A
★ 26.36
EPS
★ 0.51
N/A
Revenue
★ $29,383,000.00
N/A
Revenue This Year
$15.13
N/A
Revenue Next Year
$16.21
N/A
P/E Ratio
$13.12
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$5.98
$0.86
52 Week High
$9.81
$2.66

Technical Indicators

Market Signals
Indicator
SEVN
ALXO
Relative Strength Index (RSI) 49.08 44.49
Support Level $5.98 $1.03
Resistance Level $7.05 $1.34
Average True Range (ATR) 0.19 0.14
MACD 0.06 0.02
Stochastic Oscillator 64.21 29.49

Price Performance

Historical Comparison
SEVN
ALXO

About SEVN Seven Hills Realty Trust

Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: